What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 5 months ago
Proposed investigations (findings) in the diagnosis of Stills disease: - CRP, ESR, Ferritin (high) - W/U for infection, cancer (negative) - Serologies (negative) - consider Imaging (CXR, CT, US, PET) https://t.co/ByNSq8YACC https://t.co/BdhfRjPA6L
Dr. John Cush RheumNow
3 years 5 months ago
New podcast ready for download!
Fever Pitch--Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week.
https://t.co/GdntsVNyfS https://t.co/3QdJHNlIKQ
Dr. John Cush RheumNow
3 years 5 months ago
Should Physical exercise be recommended in dermatomyositis and polymyositis: a systematic review of 19 studies and 298 patients showed significant improvements in strength & aerobic capacity without change in CK levels or exacerbations https://t.co/G09ITAku2U https://t.co/6Mj0UAgkDE
Dr. John Cush RheumNow
3 years 5 months ago
MRP8/14 as a Biomarker in Systemic Juvenile Idiopathic Arthritis
A large cohort study of children with febrile disorders has demonstrated the diagnostic utility of MRP8/14 in diagnosing systemic JIA patients (SJIA) in clinical practice.
https://t.co/Gma3h9Iuqn https://t.co/7GOeES4bbA
Dr. John Cush RheumNow
3 years 5 months ago
RTX Induction and Maintenance in Older ANCA–Associated Vasculitis Patients
A cohort study suggests that RTX use among patients 75 years and older with ANCA–associated vasculitis (AAV) is efficacious but also has a high risk of serious adverse events.
https://t.co/HF9hyQcHZV https://t.co/xpDSohFcRK
Dr. John Cush RheumNow
3 years 5 months ago
Viscosupplementation Ineffective in kOA
The BMJ has published the results of a metanalysis showing strong conclusive evidence that viscosupplementation in kOA has minimal effects on pain/reveals strong of an increased risk of adverse events.
https://t.co/hOy0JczC4I https://t.co/Hc2rwbZS3q
Dr. John Cush RheumNow
3 years 5 months ago
Immunoprofiling of synovial CD4+ T cell subsets shows that ACPA+ pts differ from ACPA- RA by having high expression of adhesion G-protein coupled receptor 56 (GPR56) on synovial CXCL13high TPH CD4+ T cells expressing LAG-3 https://t.co/LQ77CIdh9o https://t.co/chfmLfIqeF
Dr. John Cush RheumNow
3 years 5 months ago
Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://t.co/X5CKYVFxg5 https://t.co/6HVw6AMJPL
Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com
Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://bit.ly/3RvPzDm
Dr. John Cush RheumNow
3 years 5 months ago
QD Clinic - Stills (or Not) with Hives
What do you think? 40 yr. woman with fevers, hives, and LFTs.
https://t.co/IZNnWzerOL https://t.co/sUGPuy2tKC
Antimalaria (AM) therapy is a cornerstone to the management of systemic lupus erythematosus (SLE), yet a recent study suggests that slowly tapering AM yields a lower rate of SLE flares.
Dr. John Cush RheumNow
3 years 5 months ago
mitochondrial DNA can drive SLE by PMN uptake, NETs, activation of STING & type-I IFN. Maybe same for Autoinflammatory responses were oxidized mtDNA provokes cGAS-STING, binding cytosolic NLRP3, triggering inflammasome activity. https://t.co/sTDTkoMQX2 https://t.co/wXhVzzIFRC
Dr. John Cush RheumNow
3 years 5 months ago
Steroid Injection for Chronic Achilles Tendinopathy
Adding a corticosteroid shot to exercise therapy significantly improved symptoms of chronic Achilles tendinopathy, a 100-person randomized trial found.
https://t.co/sdYmsVpBsU https://t.co/r9zFVUmE88
Poster Hall